Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_assertion type Assertion NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_head.
- NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_assertion description "[First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_provenance.
- NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_assertion evidence source_evidence_curated NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_provenance.
- NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_assertion SIO_000772 20705357 NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_provenance.
- NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_assertion wasDerivedFrom ctd_human-20130708 NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_provenance.
- NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_assertion wasGeneratedBy ECO_0000218 NP11757.RAyIgG05I4xOihfKMOnPhDbFQHDPMSRXq0uEKJYZKf5t8130_provenance.